Candonilimab

Generic Name: Candonilimab

Brand Names: -

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2394841-59-7

Unique Ingredient Identifier: 6FYG1DS4NW

Background: Cadonilimab is under investigation in clinical trial NCT04220307 (A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma).

Indication: 用于既往接受含铂化疗治疗失败的复发或转移性宫颈癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Cadonilimab
Radiation: Low-dose radiotherapy
Radiation: SBRT
Drug: Capecitabine

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Fudan University

Target Recruit Count: 52

Registration Number: NCT06494995

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2

Not yet recruiting

Conditions: HER2-positive Gastric Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Cadonilimab

First Posted Date: 2024-07-09

Last Posted Date: 2024-07-09

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 20

Registration Number: NCT06492317

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Phase 1

Recruiting

Conditions: SCLC, Extensive Stage

Interventions: Drug: AK104
Drug: Etoposide
Drug: Carboplatin
Radiation: low-dose radiotherapy

First Posted Date: 2024-06-27

Last Posted Date: 2024-06-27

Lead Sponsor: Sichuan University

Target Recruit Count: 57

Registration Number: NCT06477523

Locations: 🇨🇳
China West Hospital, Chengdu, Sichuan, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China

AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC

Phase 2

Recruiting

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Cadonilimab
Drug: Gemcitabine
Drug: Nab-Paclitaxel

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-04

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 30

Registration Number: NCT06472037

Locations: 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

Phase 2

Recruiting

Conditions: Cervical Cancer Recurrent

Interventions: Drug: AK104
Drug: Recombinant Human Adenovirus 5 Injection

First Posted Date: 2024-06-12

Last Posted Date: 2024-06-12

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 37

Registration Number: NCT06455046

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC

Phase 2

Recruiting

Conditions: NSCLC

Interventions: Drug: Cadonilimab

First Posted Date: 2024-05-22

Last Posted Date: 2024-05-22

Lead Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Target Recruit Count: 54

Registration Number: NCT06424821

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳
NINGBO No.2 Hospital, Ningbo, Zhejiang, China

Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Cadonilimab
Drug: Lenvatinib

First Posted Date: 2024-05-09

Last Posted Date: 2024-05-09

Lead Sponsor: Hunan Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT06406634

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma

Phase 3

Not yet recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: AK104
Other: Placebo for AK104
Drug: Lenvatinib
Procedure: TACE
Other: Placebo for Lenvatinib

First Posted Date: 2024-04-17

Last Posted Date: 2024-04-17

Lead Sponsor: Akeso

Target Recruit Count: 469

Registration Number: NCT06371157

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Shanxi Cancer Hospital, Taiyuan, Shanxi, China

and more 4 locations

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Phase 2

Not yet recruiting

Conditions: Advanced Soft-tissue Sarcoma

Interventions: Drug: Cadonilimab
Drug: Adriamycin

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 53

Registration Number: NCT06367075

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Phase 2

Recruiting

Conditions: Cadonilimab
Triple-negative Breast Cancer

Interventions: Drug: Cadonilimab

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 27

Registration Number: NCT06367088

Locations: 🇨🇳
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy